Khoshbayan Amin, Narimisa Negar, Elahi Zahra, Bostanghadiri Narjess, Razavi Shabnam, Shariati Aref
Microbial Biotechnology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Front Microbiol. 2024 Jun 7;15:1386478. doi: 10.3389/fmicb.2024.1386478. eCollection 2024.
Colistin is used as a last resort for managing infections caused by multidrug-resistant bacteria. However, the high emergence of colistin-resistant strains has restricted the clinical use of this antibiotic in the clinical setting. In the present study, we evaluated the global prevalence of the mutation in the gene, one of the most important mechanisms of colistin resistance in .
Several databases, including Scopus, Medline (via PubMed), and Web of Science, were searched (until August 2023) to identify those studies that address the mutation in clinical isolates of . Using Stata software, the pooled prevalence of mutation and subgroup analyses for the year of publication, country, continent, mutation types, and detection methods of mutation were analyzed.
Out of the 115 studies included in the analysis, the prevalence of mutations in colistin-resistant isolates was estimated at 65% of isolates, and variations with insertional inactivation had the highest prevalence among the five investigated mutations with 69%. The year subgroup analysis indicated an increase in mutated from 46% in 2014 to 61% in 2022. Europe had the highest prevalence of mutated at 73%, while Africa had the lowest at 54%.
Mutations in the gene are reported as one of the most common mechanisms of colistin resistance in and the results of the present study showed that 65% of the reported colistin-resistant had a mutation in this gene.
黏菌素被用作治疗多重耐药菌引起感染的最后手段。然而,耐黏菌素菌株的大量出现限制了这种抗生素在临床环境中的临床应用。在本研究中,我们评估了某基因中突变的全球流行情况,该基因是导致对黏菌素耐药的最重要机制之一。
检索了多个数据库,包括Scopus、Medline(通过PubMed)和Web of Science(截至2023年8月),以确定那些涉及该基因突变在临床分离株中的研究。使用Stata软件,分析了该基因突变的合并流行率以及按发表年份、国家、大洲、基因突变类型和基因突变检测方法进行的亚组分析。
在纳入分析的115项研究中,耐黏菌素的临床分离株中该基因突变的流行率估计为分离株的65%,在五种研究的突变中,插入失活导致的基因变异流行率最高,为69%。年份亚组分析表明,该基因突变从2014年的46%增加到2022年的61%。欧洲该基因突变的流行率最高,为73%,而非洲最低,为54%。
该基因突变被报道为导致对黏菌素耐药的最常见机制之一,本研究结果表明,65%的已报道耐黏菌素临床分离株该基因发生了突变。